Abstract
Background: Ductal adenocarcinoma of the prostate is a rare prostate cancer variant and associated with higher stage and greater risk of recurrence and mortality. Optimal systemic therapy for metastatic ductal adenocarcinoma is not known. Many case reports are needed for further understanding of clinical and molecular features about it. Herein we report the first case of a man who was diagnosed with ductal adenocarcinoma of the prostate with mitogen-activated protein kinase 1 (MAP3K1, MEKK1) homozygous deletion.Case Presentation: A 67-year-old man presented with ductal adenocarcinoma of the prostate accompanied by multiple lung metastases and advanced bone metastases. We performed channel transurethral resection of the prostate and confirmed the diagnosis of ductal adenocarcinoma of the prostate. DNA sequencing identified a TP53 somatic point mutation (p.Gly245Ser) as the pathogenic variant. Furthermore, a homozygous deletion was observed in MAP3K1 (MEKK1). The patient received enzalutamide but deceased five months after presenting to our institution.Conclusion: To our knowledge, this is the first report of ductal adenocarcinoma of the prostate with a MAP3K1 homozygous deletion. Accumulation of whole-exome sequencing data is expected to inform future advances in therapy development.
First Case of Ductal Adenocarcinoma of the Prostate with MAP3K1 Homozygous Deletion: A Case Report and Literature Review
